Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M730Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-23.7EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)19.1Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M12,450,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PJP

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

PJP is held by these investors:

PJP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48518.67view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94246.22view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1734400view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.364212.5view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381635.21view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4114204.88view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91110.14view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27835.41view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-2.87view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1539000view

Quarterly/Annual Reports about PJP:

    News about PJP:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Understanding Allergan’s Valuation after the 1Q17 Results May 11 2017
    Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus May 03 2017
    Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment Apr 26 2017
    Johnson & Johnson’s 1Q17 Segment-by-Segment Performance Apr 20 2017
    Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment Apr 13 2017
    Analyzing the Performance of Abbott Laboratories in 1Q17 Apr 11 2017
    ETF Flyers: Pharmaceuticals Apr 07 2017
    Performance of Merck & Co. Stock in 1Q17 Apr 07 2017
    These Key Product Developments Could Help Pfizer Apr 04 2017
    Recent Developments at Eli Lilly Apr 03 2017
    How Eli Lilly’s Business Segments Performed in 2016 Mar 30 2017
    Bausch & Lomb Continues to be Key Growth Driver for Valeant Mar 24 2017
    New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
    Relistor May Be Solid Growth Opportunity for Valeant in 2017 Mar 22 2017
    Billionaire Investor, Millionaire Mistakes Mar 20 2017
    Trump, Biogen and Amgen Hammer Healthcare ETFs Mar 20 2017
    Should You Buy Pharma ETFs Now? Mar 15 2017
    [$$] Drug Stocks Look Ready To Move Higher Mar 15 2017
    Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors Mar 09 2017
    The Bears Take Aim at Pharmaceuticals (PPH, PJP) Mar 08 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat